Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (494)	4/7/2005 11:03:43 PM
From: tuck	Read Replies (1) \| Respond to of 496

Count me as one of the skeptics. They bought Aggrastat on the theory that Merck had been "neglecting" the drug in the marketplace. In reality, it was up against two other similar, but better products. Message 19977057 I've disliked that buy since the the day they announced it. They paid $84 million, plus some additional royalties to Merck, and I don't think they're going to get anything like that for it, if they can find a buyer at all. I've followed GLFD for a long time, but never pulled the trigger, and still can't bring myself to. I think they're in serious trouble, and there's still more downside. Cheers, Tuck